MenuМеню
  • Home
  • About Us
  • Medicines
  • Partnering
  • Professionals
  • Responsibility
  • News & Media
  • Careers
  • Investors
  • English
  • Bulgarian

News and Media

  • Financial News
  • News
  • Opinion Pieces
  • Press Releases
  • September 12, 2018

    Tchaikapharma successfully completed the clinical trials of new dual-component fixed-dose pharmaceutical products

    Tchaikapharma completed the bioequivalence clinical trials of 4 new dual-component pharmaceutical products for the treatment of arterial hypertension and other cardiovascular diseases – with sucsess. The new drug fixed-dosage combinations with angiotensin receptor blockers and thiazide or thiazide-similar diuretics represent innovative solutions for an advanced medical care.   The researched and other already registered new […]

  • May 3, 2018

    Pizona Combi 15mg/850mg film – coated tablets – the medicine for Type 2 Diabetes treatment is the new medicinal product of “Tchaikapharma High Quality Medicines” Inc., which has been authorized by the Bulgarian Drug Agency (BDA)

    Pizona Combi contains pioglitazone and metformin that controls blood sugar levels. It helps the body to utilize better produced by body insulin when metformin alone is insufficient. The medicinal product is subject to medical prescription. For more details, please check section Products ATC код: A10B 02

  • March 29, 2018

    Tchaikapharma supported young doctors on a scientific conference in Pleven

    The 33rd National Meeting of the Association of Medical Students in Bulgaria was held in Pleven from 16 to 18 March with the support of Tchaikapharma.   A specially designed booth will welcome the participants in the eighth scientific conference of the Bulgarian Cardiac and Vascular Association under the auspices of the Rector of the […]

  • March 14, 2018

    Tchaikapharma has been awarded in Budapest

    Tchaikapharma has won award in the category of solution providers during the Pharm Connect congress which is the most notable meeting of leading pharmaceutical and biotechnology companies for Central Eastern Europe and CIS region. The excellence award was given for the successful incorporation of the latest running and implementation system. This has been a joint […]

  • April 21, 2017

    Tchaikapharma was granted Marketing Authorization for the cardiological medicinal product Ivabenor

    The newest addition to Tchaikapharma High Quality Medicines Inc. product list is Ivabenor 5 mg and 7,5 mg film-coated tablets. The cardiological medicinal product contains the active substance ivabradine. Ivabenor is indicated for the treatment of patients with chronic stable angina pectoris and chronic heart failure. ATC code: C01EB 17

  1. Previous
  2. 1
  3. ...
  4. 7
  5. 8
  6. 9
  7. 10
  8. 11
  9. 12
  10. 13
  11. ...
  12. 36
  13. Next
Copyright © 2010-2023 Tchaikapharma Inc.
  • Contact Us